

**Supplementary Table 7.** Associations between genotype of NAFLD-related SNPs and the risk of MAFLD ( $n=2,467$ )

SNP	Genotypes	
PNPLA3 rs2896019	GT/TT	GG
No. of participants	2,146	321
No. of incident MAFLD	469	81
Person-years	8,780	1,265
Adjusted model 2 <sup>a</sup>	Reference	1.29 (1.02–1.64)
GCKR rs1260326	TC/CC	TT
No. of participants	1,717	750
No. of incident MAFLD	385	165
Person-years	6,940	3,106
Adjusted model 2 <sup>a</sup>	Reference	0.99 (0.83–1.19)
GATAD2A rs4808199	GA/GG	AA
No. of participants	2,348	119
No. of incident MAFLD	522	28
Person-years	9,554	491
Adjusted model 2 <sup>a</sup>	Reference	1.09 (0.75–1.60)

Values are presented as hazard ratio (95% confidence interval).

NAFLD, non-alcoholic fatty liver disease; SNP, single nucleotide polymorphism; MAFLD, metabolic dysfunction-associated fatty liver disease; PNPLA3, patatin like phospholipase domain containing 3; A, adenine; T, thymine; C, cytosine; G, guanine; GCKR, glucokinase regulator; GATAD2A, GATA zinc finger domain containing 2A.

<sup>a</sup>Model 2 was adjusted for age, sex, body mass index, educational level, employment status, household income, energy intake per day, and family history of diseases (cardiovascular disease, hypertension, and diabetes) at baseline.